4-(2,4-二甲氧基苯基)-5-甲基-1H-吡唑-3-胺 | 863550-42-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(2,4-二甲氧基苯基)-5-甲基-1H-吡唑-3-胺
• 英文名称: 4-(2,4-Dimethoxyphenyl)-5-methyl-1H-pyrazol-3-amine
• CAS: 863550-42-9
• 化学式: C₁₂H₁₅N₃O₂
• 分子量: 233.27
• InChiKey: BAZLUEYMRVPODL-UHFFFAOYSA-N

物化性质

• 沸点：
  401.1±45.0 °C(Predicted)
• 密度：
  1.209±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  73.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2,4-二甲氧基苯基)-5-甲基-1H-吡唑-3-胺 在 三氯氧磷 作用下， 以 1,4-二氧六环 为溶剂， 生成 2,5-dimethyl-3-(2,4-dimethoxyphenyl)-7-chloropyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  Optimization of 3-phenylpyrazolo[1,5- a ]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility

  摘要：

  In our efforts to identify potent CRF1 antagonists with proper physicochemical properties, a series of 3-phenylpyrazolo[1,5-a]pyrimidines bearing polar groups, such as amino, hydroxyl, methoxy, sulfoxide, were designed and synthesized. Several positions of the core structure were identified, where a polar group was tolerated with slight reduction in receptor binding. NBI 30545 (18n) was found to have good binding affinity and potent antagonistic activity at the human CRF1 receptor. Moreover, this compound had proper lipophilicity (log D = 2.78) and good solubility in water (>10 mg/mL), and exhibited good plasma and brain exposure when given orally. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.019
• 作为产物：
  描述：

  2-(2,4-二甲氧基苯基)乙腈 在 盐酸肼 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 4-(2,4-二甲氧基苯基)-5-甲基-1H-吡唑-3-胺
  参考文献：
  名称：

  Optimization of 3-phenylpyrazolo[1,5- a ]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility

  摘要：

  In our efforts to identify potent CRF1 antagonists with proper physicochemical properties, a series of 3-phenylpyrazolo[1,5-a]pyrimidines bearing polar groups, such as amino, hydroxyl, methoxy, sulfoxide, were designed and synthesized. Several positions of the core structure were identified, where a polar group was tolerated with slight reduction in receptor binding. NBI 30545 (18n) was found to have good binding affinity and potent antagonistic activity at the human CRF1 receptor. Moreover, this compound had proper lipophilicity (log D = 2.78) and good solubility in water (>10 mg/mL), and exhibited good plasma and brain exposure when given orally. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.019

文献信息

• [EN] CRF RECEPTOR ANTAGONISTS, THEIR PREPARATIONS, THEIR PHARMACEUTICAL COMPOSITION AND THEIR USES<br/>[FR] ANTAGONISTES DU RECEPTEUR DE LA CORTICOLIBERINE, LEUR PREPARATION, LEUR COMPOSITION PHARMACEUTIQUE ET LEURS UTILISATIONS
  申请人：SB PHARMCO INC

  公开号：WO2005079868A3

  公开（公告）日：2006-01-26
• AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES
  申请人：NEUROGEN CORPORATION

  公开号：EP1218381B1

  公开（公告）日：2006-12-06
• Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses
  申请人：Grigoriadis Dimitri

  公开号：US20070129382A1

  公开（公告）日：2007-06-07

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in warm-blooded animals. CRF receptor antagonists which are labeled with a positron emitting isotope for use in PET are also disclosed.
• US6476038B1
  申请人：——

  公开号：US6476038B1

  公开（公告）日：2002-11-05